GNRH1 and uveal melanoma: AEZS-108 (previously known as AN-152), a hybrid molecule consisting of a synthetic peptide carrier covalently coupled to DOX, was found to facilitate the delivery of DOX specifically to cancer cells expressing LHRH, including in uveal melanoma [123] and prostate cancer [124].